Gut-thyroid axis and celiac disease
MT-II is an alpha-melanocyte-stimulating hormone (-MSH) analogue that binds to MC1R receptors on melanocytes, triggering a cascade that prepares cells for eumelanin synthesis
Automated Alerts: Patients can sign-up to receive automated email alerts, delivered when a GLP-1 drug is reported in supply in their area or when the status of a GLP-1 drug changes on the FDA's Drug Shortage List
doi: 10.1016/j.phrs.2020.104722
In practice, the SAFE Drugs Act: Reduces tolerance for informal workarounds Strengthens the FDAs enforcement posture Signals congressional intent to limit unauthorized distribution of approved drugs As a result, arguments that once relied on disclaimers alone are far weaker under the SAFE Drugs Act
The medications unique power lies in its ability to mimic the GLP-1 hormone, which effectively modulates key hunger and satiety signals in the brain and slows gastric emptying, leading to a sustainable reduction in caloric intake
